Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. - Wikidata - awgldk - TriplyDB

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.

http://www.wikidata.org/entity/Q42202640

about

Recent Advances in Antiviral Therapy for Chronic Hepatitis C Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease Advances in hepatitis C therapy: What is the current state - what come's next?Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis Hepatitis C genotype 4: The past, present, and future Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6 Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis The new era of hepatitis C virus therapy Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.Hepatitis C treatment: where are we now?Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis.Direct-acting antivirals for chronic hepatitis C.Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens.Predictive factors associated with hepatitis C antiviral therapy response.Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24.Impact of hepatitis C status on 20-year mortality of patients with substance use disorders.Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1 Management of hepatitis C genotype 4 in the directly acting antivirals era.How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.Optimal therapy in genotype 4 chronic hepatitis C: finally cured?Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection.Advances in hepatitis C therapies.Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.Daclatasvir for the treatment of chronic hepatitis C.Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions.In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence.Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients.Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview.New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs).Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015).Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.

P2860

Q26750476-B72C305B-DB5D-41F4-A38F-6234EC93B115 Q26752433-D7351869-8FF7-4F3A-93B1-CFD800F917BE Q26770036-867DD54C-0DDD-4D94-BC4A-C563D84DFB68 Q26771458-073B086E-5433-4B18-86C0-E519B260CD2E Q26775815-B0D7E15B-4947-43FC-8393-7ADB201D4BDB Q26828972-6BEE3BC4-B682-4835-BE56-BC2173E08597 Q28073108-0CFCF8AD-BAE2-4026-B2AA-DE0C8A86E75C Q28077287-98993A3F-5432-464C-932C-E1051B506AB1 Q28086947-9714BF9F-1AFA-41C1-931F-75095614CB67 Q30355190-7574C6A3-2326-4B97-AEDD-B36CF9985348 Q30378509-ACF96A96-9001-4458-8618-13BF7DD2A3B5 Q31121312-EA4F44D3-26EA-4907-A369-71AED5D08FE8 Q34522481-0164D36E-5B5A-4497-89D9-62980EC98AEB Q34557595-40B8FFD6-0EC6-49A9-8ECF-8A10532615DB Q35783876-44051A00-3D00-4303-80BC-1315732A4EB8 Q35790397-C45ADC1C-BECD-4C43-80B7-203380C15B42 Q35862004-43430007-846A-423D-A8FF-59A19004F067 Q36158361-A781AC75-3CDE-44A5-969B-46D5A419CA5B Q36167257-8852D51D-A41A-4F05-A2EB-09BE8E30B030 Q36354119-FD8C3EB1-888B-453E-8D81-6A8DBF4AAEBB Q36531731-915E343B-B0CB-4A39-8FB2-63FFCF76E11B Q36724391-E5CD5CD1-26E0-4442-B5F5-97208484D0D1 Q37312151-37E264F2-0BEA-438F-8F4A-FF9A246BD63B Q38295807-DB437F63-0EB7-4C18-8C8B-BB244D5F1F1E Q38295814-A0427DC1-EBE1-40B1-BCD3-E43531E49D06 Q38503778-0295C4C1-E67A-4C75-BAA4-EA8C3BE0AD75 Q38556401-5F81DDFA-AB33-4FF9-A86F-05C643043744 Q38602682-CADD8AD5-38F4-4C82-97D0-3628BB525878 Q38612647-EE81C38F-6E02-4313-8502-E163AD39C247 Q38628237-3B451389-0254-447D-934D-5F6D25C5929F Q38728564-3696DACA-46B3-4B68-83D3-7FB100AACA3D Q38740523-FD97F9F6-9256-4605-B737-F96952CAA292 Q38859473-037B2B9D-289F-40FF-8CE5-0FFF4B65F4AD Q38991020-9B8D1CA6-8418-4FF1-97C0-1C7DB819E999 Q39007700-80D9E1E6-E6C4-48E5-8B73-B2DECC27B96E Q39015799-106A662B-8CDB-4FB6-8F98-6B80AE337D01 Q39016874-3B4F5993-0AE1-4C0F-A05A-F95303A7E5BA Q39038238-C93DFB01-FAD0-48ED-B9DD-8757BDB3F4E4 Q39099624-EE8DD52C-47F4-43F2-9BC6-DB0D9215851C Q39104215-08DD179C-42F5-4125-B354-16C9F3999B0B

P2860

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.

http://www.wikidata.org/entity/Q42202640

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Daclatasvir plus peginterferon ...... infection: a randomised study.

@en

Daclatasvir plus peginterferon ...... infection: a randomised study.

@nl

type

label

Daclatasvir plus peginterferon ...... infection: a randomised study.

@en

Daclatasvir plus peginterferon ...... infection: a randomised study.

@nl

prefLabel

Daclatasvir plus peginterferon ...... infection: a randomised study.

@en

Daclatasvir plus peginterferon ...... infection: a randomised study.

@nl

P1433

Q42202640-936A7122-406F-4EB2-B05C-73100147B574

P1476

Q42202640-82A9484C-373E-4C4C-AC16-592770384167

P2093

Q42202640-19C645DA-ED3F-4986-B692-F3EC4F9D725B

Q42202640-257E0214-0859-405E-A9F6-4AAE189AE2DB

Q42202640-2B9FD65D-FC93-4FDF-BD76-5F8C519055A7

Q42202640-30436F76-97AE-4CA4-BECE-BB0101409E85

Q42202640-3614456B-A044-456E-A119-EEEFDF87570B

Q42202640-3908AC0C-FE62-42D0-80AB-6A5C8C2CA810

Q42202640-3AF9F7F3-85B7-4678-A89E-6E29B553CE60

Q42202640-3D7EB3FE-EAB4-446E-9A6C-09428C0CA075

Q42202640-55F1B63D-07BE-40E6-A9B8-4F21208483BF

Q42202640-58250FA2-9EA5-4EC2-A457-E2E2CCB47A3E

P2860

Q42202640-12434C35-5357-4957-9689-D73AFE056448

Q42202640-13ABD5F3-043D-4652-8FB3-C33F97868654

Q42202640-1622A968-A960-49F6-B95C-742A03969453

Q42202640-1B58891A-5E45-4E29-886E-82DBBCB0EEDE

Q42202640-1FCD2956-E45E-4B4E-B41E-B884DD41860B

Q42202640-29BB3963-8840-4171-BC2B-1DBDA032B534

Q42202640-2F59C13B-921E-4D9C-BA4F-7F32F0ACE35C

Q42202640-3008838B-848D-46C2-8D86-A0364A2CF850

Q42202640-466E464C-0EFC-4E4E-8FD5-CCFC1657FBB4

Q42202640-528F8A5C-0108-4DC4-BFB0-B93F994DCAED

P304

Q42202640-7CD4432B-A3CB-4C8A-8C8B-3487AB87B8B3

P31

Q42202640-EC80E28C-2F37-4279-88E4-E42214245D13

P356

Q42202640-DC2F8635-1CE7-45DE-B090-C9B7E5969158

P407

Q42202640-855B4FDA-161B-4E6D-BA8B-4897418D292A

P433

Q42202640-D5D90D4E-4998-4F3D-B3E8-C27DD911AF73

P478

Q42202640-D93D23DB-304D-4A8D-83E0-92393B882F30

P50

Q42202640-070A3C03-8F10-4528-A4BB-2788C9AD3EA5

Q42202640-49F09C18-72F0-49C8-8632-4CD60BDDA2E5

Q42202640-4A2BA0D8-3086-43FB-AB55-0553F37C6C8E

Q42202640-625901B5-B5DE-4ADD-AA7E-AD602FF2E614

Q42202640-9B3B4ECF-CB16-4718-AD42-A0A6E0807447

Q42202640-A42B2C83-8139-422B-A902-653B35DF8024

Q42202640-C32FBE49-D770-4B03-8B12-6C1283836EA9

Q42202640-E140E0AA-9C28-4271-B203-10E3A2D1C6E2

Q42202640-F752CD10-CA03-4F9B-8491-9A75628F976F

P577

Q42202640-DB52577C-A053-4FA6-9456-AC062D294303

P5875

Q42202640-3961B85F-6FD2-48F2-9CE9-1F69E1BE78C3

P698

Q42202640-B5F39A10-F4D8-4121-8731-00F62C77AA32

P921

Q42202640-A740345F-5EBE-442E-AF1B-3126D04ACFB5

P356

GUTJNL-2014-307498

P1433

P1476

Daclatasvir plus peginterferon ...... infection: a randomised study.

@en

P2093

Christophe Hézode

http://www.w3.org/2001/XMLSchema#string

Dennis Hernandez

http://www.w3.org/2001/XMLSchema#string

Eric A Hughes

http://www.w3.org/2001/XMLSchema#string

Eric J Lawitz

http://www.w3.org/2001/XMLSchema#string

Fiona McPhee

http://www.w3.org/2001/XMLSchema#string

Gamal Esmat

http://www.w3.org/2001/XMLSchema#string

Gregory T Everson

http://www.w3.org/2001/XMLSchema#string

Harvey A Tatum

http://www.w3.org/2001/XMLSchema#string

John M Vierling

http://www.w3.org/2001/XMLSchema#string

Lawrence Serfaty

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

Diagnosis, management, and treatment of hepatitis C: an update

Telaprevir for previously untreated chronic hepatitis C virus infection

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

Sofosbuvir for previously untreated chronic hepatitis C infection

The global burden of hepatitis C

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt.

Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein.

P304

948-956

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUTJNL-2014-307498

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P50

Gideon M. Hirschfield

Christophe Hézode

Megan Wind-Rotolo

Maurizia R Brunetto

P577

2014-07-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264634339

http://www.w3.org/2001/XMLSchema#string

P698

25080450

http://www.w3.org/2001/XMLSchema#string

P921